Skip to main content

Table 2 Mean visits per patient per year—any autoimmune condition and lupus erythematosus

From: Hereditary angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database

Any autoimmune condition

Medication cohort

Number of patientsa

Total f/u years

Number of visits

Autoimmune visits

Autoimmune visits per patient per f/u year

Mean (SD)

95% CI

LB

95% CI

UB

Range

p-valueb

All

Other non-C1-INH

276

729

62,864

1528

2.3 (12.22)

0.832

3.727

0–107.03

0.7369

pdC1-INH

313

860

85,859

1381

1.4 (7.30)

0.562

2.185

0–107.08

 

< 50 years

 Male

Other non-C1-INH

56

136

6087

66

0.6 (3.21)

− 0.213

1.505

0–21.97

0.0733

pdC1-INH

45

120

8082

0

0.0 (0.00)

0.000

0.000

0.0000

 

 Female

Other non-C1-INH

110

286

29,465

1188

4.7 (18.69)

1.178

8.243

0–107.03

0.6410

pdC1-INH

146

386

44,613

1004

2.0 (9.79)

0.381

3.583

0–107.08

 

Lupus

 All

Other non-C1-INH

276

729

62,864

324

0.6 (6.92)

− 0.189

1.451

0–105.23

0.375

pdC1-INH

313

860

85,885

357

0.4 (2.65)

0.078

0.667

0–26.14

 

< 50 years

 Male

Other non-C1-INH

56

136

6087

0

0.0 (0.00)

0.000

0.000

0–0

1.0000

pdC1-INH

45

120

8082

0

0.0 (0.00)

0.000

0.000

0–0

 

 Female

Other non-C1-INH

110

286

29,465

315

1.6 (10.92)

− 0.499

3.629

0–105.23

0.6040

pdC1-INH

146

386

44,613

236

0.5 (2.68)

0.025

0.900

0–25.91

 
  1. pdC1-INH treatment = Cinryze and Berinert and “Other non-C1-INH treatment” = Firazyr and Kalbitor
  2. C1-INH C1-inhibitor, CI confidence interval, f/u follow-up, LB lower bound, pd plasma-derived, SD standard deviation, UB upper bound
  3. a14 patients were missing age (8 females and 6 males)
  4. bTwo-sided Wilcoxon rank sum test